We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
BRIUMVI (Accelagen Pty Ltd)
Product name
BRIUMVI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
101 (255 working days)
Active ingredients
ublituximab
Registration type
NCE/ NBE
Indication
BRIUMVI is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.